Lv4
550 积分 2024-04-11 加入
DOAC-Stop™ reverses the anticoagulant effect of asundexian and milvexian
2个月前
已关闭
A single-arm phase 2 trial of an investigational RNA therapeutic to complement factor B sefaxersen for treatment of IgA nephropathy
3个月前
已关闭
The incidence of primary glomerulonephritis worldwide: a systematic review of the literature
5个月前
已完结
A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy
5个月前
已完结
Atrasentan in Patients with IgA Nephropathy
5个月前
已完结
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy
5个月前
已完结
Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3
6个月前
已完结
Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial
6个月前
已完结
Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines
6个月前
已完结
An MDS Evidence‐Based Review on Treatments for Huntington's Disease
6个月前
已完结
皖公网安备34019202002308
